EyePoint Pharmaceuticals Inc (PSDV):企業の財務・戦略的SWOT分析

◆英語タイトル:EyePoint Pharmaceuticals Inc (PSDV) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDME3119FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥64,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥97,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
EyePoint Pharmaceuticals Inc (EyePoint), formerly pSivida Corp, is a biopharmaceutical company that provides development of miniaturized, sustained-release drug delivery products and technologies. The company offers products such as iluvien, retisert and durasert, among others. EyePoint durasert is an injectable, miniaturized, sustained-release drug delivery system, used for the treatment of chronic diseases of the back of the eye. The company’s iluvien is an injectable, non-erodible, intravitreal implant for the treatment of DME. EyePoint provides drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. The company operates in the US and the UK. EyePoint is headquartered in Watertown, Massachusetts, the US.

EyePoint Pharmaceuticals Inc Key Recent Developments

Feb 25,2021: EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021
Oct 08,2020: EyePoint Pharmaceuticals announces amendment to CRG debt facility modifying 2020 and 2021 revenue covenants
Oct 07,2020: EyePoint Pharmaceuticals announces preliminary net product revenue for third quarter 2020
Aug 05,2020: EyePoint Pharmaceuticals reports second quarter 2020 financial results and highlights recent corporate developments
Jul 13,2020: EyePoint Pharmaceuticals expands executive leadership team with the appointment of Jay S. Duker, M.D., as chief strategic scientific officer

This comprehensive SWOT profile of EyePoint Pharmaceuticals Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of EyePoint Pharmaceuticals Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

EyePoint Pharmaceuticals Inc – Key Information
EyePoint Pharmaceuticals Inc – Overview
EyePoint Pharmaceuticals Inc – Key Employees
EyePoint Pharmaceuticals Inc – Key Employee Biographies
EyePoint Pharmaceuticals Inc – Key Operational Heads
EyePoint Pharmaceuticals Inc – Major Products and Services
EyePoint Pharmaceuticals Inc – History
EyePoint Pharmaceuticals Inc – Company Statement
EyePoint Pharmaceuticals Inc – Locations And Subsidiaries
EyePoint Pharmaceuticals Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

EyePoint Pharmaceuticals Inc – Business Description
EyePoint Pharmaceuticals Inc – Corporate Strategy
EyePoint Pharmaceuticals Inc – SWOT Analysis
SWOT Analysis – Overview
EyePoint Pharmaceuticals Inc – Strengths
EyePoint Pharmaceuticals Inc – Weaknesses
EyePoint Pharmaceuticals Inc – Opportunities
EyePoint Pharmaceuticals Inc – Threats
EyePoint Pharmaceuticals Inc – Key Competitors

Section 3 – Company Financial Performance Charts

EyePoint Pharmaceuticals Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

EyePoint Pharmaceuticals Inc, Key Information
EyePoint Pharmaceuticals Inc, Key Ratios
EyePoint Pharmaceuticals Inc, Share Data
EyePoint Pharmaceuticals Inc, Major Products and Services
EyePoint Pharmaceuticals Inc, History
EyePoint Pharmaceuticals Inc, Key Employees
EyePoint Pharmaceuticals Inc, Key Employee Biographies
EyePoint Pharmaceuticals Inc, Key Operational Heads
EyePoint Pharmaceuticals Inc, Other Locations
EyePoint Pharmaceuticals Inc, Subsidiaries
EyePoint Pharmaceuticals Inc, Key Competitors
EyePoint Pharmaceuticals Inc, SWOT Analysis
EyePoint Pharmaceuticals Inc, Ratios based on current share price
EyePoint Pharmaceuticals Inc, Annual Ratios
EyePoint Pharmaceuticals Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[EyePoint Pharmaceuticals Inc (PSDV):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Severstal:企業の戦略・SWOT・財務情報
    Severstal - Strategy, SWOT and Corporate Finance Report Summary Severstal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • pSivida Corp (PSDV)-医療機器分野:企業M&A・提携分析
    Summary pSivida Corp (pSivida) is a specialty pharmaceutical company that offers development of miniaturized, sustained-release drug delivery products and technologies. The company’s products include iluvien, retisert and durasert. Its durasert is an injectable, miniaturized, sustained-release drug …
  • Ion Beam Applications SA (IBAB):医療機器:M&Aディール及び事業提携情報
    Summary Ion Beam Applications SA (IBA) develops solutions for the diagnosis and treatment of cancer. It offers monitoring equipment and software that enables hospitals to perform calibration procedures during radiation therapy and radiology. The company focuses its activities on proton therapy solut …
  • The AES Corporation:企業の戦略・SWOT・財務分析
    The AES Corporation - Strategy, SWOT and Corporate Finance Report Summary The AES Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Town Health International Medical Group Ltd (3886):企業の財務・戦略的SWOT分析
    Summary Town Health International Medical Group Ltd (THIMGL), formerly Town Health International Investments Ltd, a subsidiary of Hong Kong Health Check and Medical Diagnostic Group Ltd, is a healthcare service provider. The organization offers medical platform, chain clinics, specialty centres, man …
  • Kancera AB (KAN):製薬・医療:M&Aディール及び事業提携情報
    Summary Kancera AB (Kancera) is a developer of drug candidates for the treatment of cancer. The company’s pipeline products include fractalkine inhibitor AZD8797, used to stop tumor growth; small molecule HDAC6 inhibitors, for neutralizing blood cancer; small molecule PFKFB3 inhibitors, for stopping …
  • Frequency Therapeutics Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Frequency Therapeutics Inc (Frequency Therapeutics) is a biotechnology company that develops progenitor cell activation (PCA) therapies. The company’s small molecule drugs are used to activate progenitor cells for restoration of healthy tissue. Its lead program FX-322 is used to recreate sen …
  • NPC Co., Ltd.:企業の戦略・SWOT・財務情報
    NPC Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary NPC Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Slovenske elektrarne, a.s.-エネルギー分野:企業M&A・提携分析
    Summary Slovenske elektrarne, a.s. (Slovenske), is an electric utility company that generates, distributes and trades electricity. It also generates and markets heat and offers ancillary services to the power industry. The company generates electricity through various resources such as conventional …
  • Sequella Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sequella Inc (Sequella) is a clinical-stage pharma company that develops antibiotics to address drug resistant bacterial, fungal, and parasitic infections. The company’s pipeline products comprise SQ109, Sutezolid, SQ641 and SQ609; and a novel rapid antibiotic susceptibility test, B-SMART. S …
  • Emerson Electric Co (EMR):石油・ガス:M&Aディール及び事業提携情報
    Summary Emerson Electric Co. (Emerson) is a provider of infrastructure technologies and life cycle services for information and communication technology systems. The company offers hardware and software solutions for power, thermal and infrastructure management under the brands of Kop-Flex, jaure, a …
  • Handok Inc (002390)-製薬・医療分野:企業M&A・提携分析
    Summary Handok Inc (Handok), formerly known as Handok Pharmaceuticals Co Ltd, is a pharmaceutical and health care company which develops, manufactures and distributes healthcare solutions. The company develops and provides pharmaceutical products including prescription drugs, OTC drugs, medical devi …
  • Hyundai Heavy Industries Co., Ltd.:企業の戦略・SWOT・財務情報
    Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Hyundai Heavy Industries Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Saudi Electricity Co (5110):企業の財務・戦略的SWOT分析
    Saudi Electricity Co (5110) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakness …
  • NanoCarrier Co Ltd (4571):企業の財務・戦略的SWOT分析
    Summary NanoCarrier Co Ltd (NanoCarrier) is a drug development company that develops and produces pharmaceuticals using micellar nanoparticles technology. The company’s pipeline products include NC-6004, NC-4016, NC-6300, VB-111, NC-6201 and NK105. It offers siRNA micelle, protein micelle, DACH-plat …
  • Kennametal Inc.:企業の戦略・SWOT・財務情報
    Kennametal Inc. - Strategy, SWOT and Corporate Finance Report Summary Kennametal Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Polski Koncern Naftowy Orlen SA (PKN):石油・ガス:M&Aディール及び事業提携情報
    Summary Polski Koncern Naftowy Orlen SA (PKN Orlen) is an integrated oil and gas company. It explores for and produces crude oil and natural gas; manufactures petroleum products; transports and sells crude oil and petroleum products; and markets natural gas and natural gas liquids. Its product portf …
  • Chugai Pharmaceutical Co Ltd (4519):製薬・医療:M&Aディール及び事業提携情報
    Summary Chugai Pharmaceutical Co Ltd (Chugai) is a subsidiary of Hoffmann-La Roche Ltd, which focuses on the research, development, manufacture, commercialization, import and export of the biopharmaceuticals and therapeutic antibodies. The company offers products for the treatment of cancer; bone an …
  • China Construction Bank Corp:企業のM&A・事業提携・投資動向
    China Construction Bank Corp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Construction Bank Corp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • Otello Corp ASA (OTELLO):企業の財務・戦略的SWOT分析
    Otello Corp ASA (OTELLO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆